123TiP - Study 20070782: randomized phase 3 trial of the long-term safety of darbepoetin alfa in patients with non-small cell lung cancer (NSCLC) with chemot...
|Date||28 March 2014|
|Session||Lunch and poster display session|
|Topics|| Complications of Treatment
Non-Small-Cell Lung Cancer, Metastatic
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
P. Gascon1, C.H. Barrios2, D. Gordon3, V. Hirsh4, S. Orlov5, K. Syrigos6, C. Volovat7, L. Zhang8, C. Bohac9
Controlled trials have shown erythropoiesis-stimulating agents (ESAs) raise hemoglobin (Hb) and reduce transfusions in patients with CIA. While some suggestions of increased mortality and/or tumor progression have been raised in a few trials, most studies to date have not associated the use of ESAs with worse outcomes. As CIA often develops in lung cancer, studying ESA safety in NSCLC is warranted.